EN DE
STOCK COMPARISON

Penumbra vs Abbott Laboratories: Fair Value & Quality

Both stocks run through our valuation models. Here is how Penumbra (PEN) and Abbott Laboratories (ABT) compare, as of Aug 8, 2026.

As of Aug 8, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Penumbra trades at $325 versus a fair value of $76.80 (-76%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Penumbra
PEN · USD · Health Care
-76%
upside to fair value
overvalued
Price$325
Fair Value$76.80
Quality69/100
Abbott Laboratories
ABT · USD · Health Care
-31%
upside to fair value
overvalued
Price$108
Fair Value$74.79
Quality64/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

PenumbraAbbott Laboratories
Valuation
73.0×P/E (TTM)27.7×
8.64×P/S (TTM)3.89×
8.81×P/B3.36×
60.7×EV/EBITDA15.1×
4.06×PEG1.47×
Profitability
12%Net margin14%
10%Operating margin13%
13%Return on equity12%
7%Return on assets6%
Growth
16%Revenue growth (YoY)8%
18.3%Avg. growth/yr (3Y)0.5%
20.2%Avg. growth/yr (5Y)5.1%
Balance & size
—Debt / equity0.19×
$13BMarket cap$175B
healthyGrowth qualityhealthy

Abbott Laboratories leads: 5 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Penumbraof which business quality 71 · market factors 63 Abbott Laboratoriesof which business quality 66 · market factors 51
ProfitabilityMargins and returns on capital today
64
50
Quality GrowthAre margins and returns improving?
82
47
CashflowEarnings quality: real cash, not paper profit
60
71
Fin. StrengthBalance sheet, leverage, solvency risk
87
80
InvestmentDisciplined investing over empire-building
58
65
Low VolatilityCalm price path (market factor)
76
83
MomentumPrice trend over the last 3–12 months (market factor)
48
40
52W MomentumDistance to the 52-week high (market factor)
72
34
Net IssuanceBuybacks instead of dilution
75
84

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Penumbra

DCF Models$124
Earnings-Based$101
Dividend Discount$3.60
Multiples$76.80
Asset-Based$24.32
Growth DCF$124
Economic Profit$56.61
Growth Earnings$131

26 of 26 models see the stock below the current price.

Abbott Laboratories

DCF Models$70.99
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$69.29
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$64.43

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Penumbra
Bear $57.60Fair Value $76.80Bull $130
$325 = current price (white tick)
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$108 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Penumbra · Health Care

Quality score69 · Top 25%
Fair value upside-76% · bottom 25%

Abbott Laboratories · Health Care

Quality score64 · Top 25%
Fair value upside-31% · below median

Bottom line

As of Aug 8, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Penumbra trades at $325 versus a fair value of $76.80 (-76%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).

Penumbra has the higher quality score (69/100).

See the full analysis →
Penumbra · Abbott Laboratories

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Penumbra

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to Abbott Laboratories

UnitedHealth Group vs Abbott LaboratoriesUnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs Amgen
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.